Touzeau Cyrille, Raguideau Fanny, Denis Hélène, Lamarsalle Ludovic, Guilmet Caroline, Javelot Matthieu, Pierres Marie, Perrot Aurore
Centre Hospitalier Universitaire de Nantes, Nantes, France.
HEVA, Lyon, France.
PLoS One. 2025 May 8;20(5):e0322474. doi: 10.1371/journal.pone.0322474. eCollection 2025.
Management of multiple myeloma (MM) has evolved in the last decade, impacting epidemiology and creating the need for a revised algorithm for patient identification in the French National Health Insurance database (SNDS). The objective of the MYLORD study was to provide up-to-date epidemiological indicators for MM using the SNDS.
Adults treated for MM between 2014 and 2020 were identified using hospital stays (ICD-10 code C90*) and/or Long-Term Disease status for MM (ICD-10 C90*) and treatment dispensation (MM specific treatments), or lenalidomide or thalidomide with 2 conditions: at least 2 Serum or Urine-Protein Electrophoresis performed within 4 months after the first drug dispensing and no hospital stays for other indications than MM.
In 2020 in France, the number of new patients treated for MM was estimated at 5,608, corresponding to a world age-standardized incidence rate (ASIR) of 3.67 (3.55-3.78) per 100,000 patients. The total number of patients treated for MM was estimated at 33,675 corresponding to a world age-standardized prevalence rate (ASPR) of 22.34 (22.06-22.63) per 100,000 patients. The world ASIR slightly increased from 2014 to 2018, then slightly decreased until 2020. There is a regular increase of the ASPR every year in both men and women.
The algorithm developed for the MYLORD study considerably improves the identification of patients treated for MM in the SNDS compared to the current French references and allows to generate robust epidemiological indicators. The stable incidence and the increase in prevalence from 2014 to 2020 reflect the improvement in therapeutic management over the years.
在过去十年中，多发性骨髓瘤（MM）的管理方式发生了演变，这对流行病学产生了影响，并使得法国国家健康保险数据库（SNDS）中需要一种经过修订的患者识别算法。MYLORD研究的目的是利用SNDS提供MM的最新流行病学指标。
通过住院记录（国际疾病分类第十版代码C90*）和/或MM的长期疾病状态（国际疾病分类第十版C90*）以及治疗配给（MM特异性治疗），或来那度胺或沙利度胺，并满足两个条件来识别2014年至2020年期间接受MM治疗的成年人：在首次药物配给后4个月内至少进行2次血清或尿蛋白电泳，且没有因MM以外的其他指征住院。
2020年在法国，估计接受MM治疗的新患者数量为5608例，相当于世界年龄标准化发病率（ASIR）为每10万患者3.67（3.55 - 3.78）例。估计接受MM治疗的患者总数为33675例，相当于世界年龄标准化患病率（ASPR）为每10万患者22.34（22.06 - 22.63）例。世界ASIR从2014年到2018年略有上升，然后到2020年略有下降。男性和女性的ASPR每年都有规律地上升。
与当前法国的参考标准相比，为MYLORD研究开发的算法显著改善了SNDS中接受MM治疗患者的识别，并能够生成可靠的流行病学指标。2014年至2020年发病率稳定且患病率上升，反映了多年来治疗管理的改善。
